Business
BioInvent Announces Nomination of Two New Board Members Ahead of 2026 Annual General Meeting
Kate Hermans: Global life sciences executive with 25+ years of leadership across biopharma, commercial strategy, global operations, and value-creation transformations in both public and venture-backed companies Scott Zinober: Senior investment professional ...
About this update from Bioinvent International Ab
[{"type":"list","items":[{"val":[{"type":"text","content":"Kate Hermans: Global life sciences executive with 25+ years of leadership across biopharma, commercial strategy, global operations, and value-creation transformations in both public and venture-backed companies","length":210,"tagName":"p"}]},{"val":[{"type":"text","content":"Scott Zinober: Senior investment professional with 25 years global experience with focus on public companies, including two decades as senior portfolio manager at Viking Global Investors","length":186,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":396,"olType":false},{"type":"text","content":"LUND, SE / ACCESS Newswire / February 23, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV)(STO:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced the nomination of. Kate Hermans and Scott Zinober as new members of the Board of Directors. Their elections will be put forward for shareholder approval at the Annual General Meeting (AGM) on April 29, 2026. While the formal notice to the AGM will be published in March, BioInvent is pleased to share these nominations in advance given the strategic, operational, and financial leadership both candidates bring to the Company.","length":719,"tagName":"p"},{"type":"text","content":""We are delighted to nominate Kate Hermans and Scott Zinober to the BioInvent Board," said Leonard Kruimer, Chairman of the BioInvent Board of Directors. "Kate brings valuable global operating experience and a track record of transforming and accelerating growth across biopharma organizations. Her commercial, strategic, and leadership experience will benefit BioInvent as our pipeline matures toward late-stage development and commercialization. Scott's experience in global healthcare investment and especially US capital markets insights will be key to developing viable financing strategies for the company going forward. As prospective new board members Kate's and Scott's experience in healthcare will broaden the board capabilities as we execute on our clinical strategy, advance our lead clinical candidates BI-1808 and BI-1206, and strengthen BioInvent's position as a global immuno-oncology innovator."","length":949,"tagName":"p"}...